AbbVie Inc. (ABBV) FCF Payout Ratio: 57.51%
Is AbbVie Inc.’s FCF payout ratio high or low?
AbbVie Inc.'s FCF payout ratio of 57.51% is 13% above its 5-year average of 50.75%, around the middle of its 5-year range (41.42%–65.43%).
The FCF payout ratio for AbbVie Inc. (ABBV) is 57.51%. It is below its 12-month average by 9.62% (63.63%).
ABBV FCF Payout Ratio Chart
ABBV Average FCF Payout Ratio Chart
ABBV Current vs Average FCF Payout Ratio Chart
ABBV FCF Payout Ratio Metrics
FCF PAYOUT RATIO
57.51%
FCF PAYOUT RATIO AVG TTM
63.63%
FCF PAYOUT RATIO AVG 3Y
54.11%
FCF PAYOUT RATIO AVG 5Y
50.75%
FCF PAYOUT RATIO AVG 10Y
49.57%
FCF PAYOUT RATIO AVG 15Y
52.31%
FCF PAYOUT RATIO AVG 20Y
52.31%
CURRENT VS TTM AVG
-9.62%
CURRENT VS 3Y AVG
+6.28%
CURRENT VS 5Y AVG
+13.31%
CURRENT VS 10Y AVG
+16.03%
CURRENT VS 15Y AVG
+9.94%
CURRENT VS 20Y AVG
+9.94%
Payout Ratio Comparison
FCF Payout Ratio
57.5%
Earnings Payout Ratio
284.4%
Dividend Yield
2.99%
FCF Yield
5.22%
Annual FCF Payout Ratio History
| Year | Free Cash Flow | Dividends Paid | FCF Payout Ratio |
|---|---|---|---|
| 2025 | $17.82B | $11.66B | 65.4% |
| 2024 | $17.83B | $11.03B | 61.8% |
| 2023 | $22.06B | $10.54B | 47.8% |
| 2022 | $24.25B | $10.04B | 41.4% |
| 2021 | $21.99B | $9.26B | 42.1% |
| 2020 | $16.79B | $7.72B | 46.0% |
| 2019 | $12.77B | $6.37B | 49.8% |
| 2018 | $12.79B | $5.58B | 43.6% |
| 2017 | $9.43B | $4.11B | 43.5% |
| 2016 | $6.56B | $3.72B | 56.6% |
| 2015 | $7.00B | $3.29B | 47.0% |
| 2014 | $2.94B | $2.66B | 90.6% |
| 2013 | $5.78B | $2.56B | 44.2% |
| 2012 | $6.01B | $0 | 0.0% |
| 2011 | $5.89B | $0 | 0.0% |
| 2010 | $4.53B | $0 | 0.0% |
| 2009 | $5.05B | $0 | 0.0% |
Formula: FCF Payout Ratio = Dividends Paid / Free Cash Flow × 100
FCF payout and earnings payout:
- FCF represents operating cash flow after capital expenditures
- FCF payout compares dividends paid with free cash flow
- FCF payout above 100% means dividends paid exceeded free cash flow for the period
- Earnings payout compares dividends paid with net income
Reading the series: Use the chart and table to compare dividend payments with cash generation over time.
AbbVie Inc. FCF Payout Ratio Formula & Definition
FCF Payout Ratio measures what percentage of free cash flow is paid out as dividends. Unlike earnings-based payout, it compares dividends with cash generated after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
AbbVie Inc. FCF Payout Ratio FAQ
- What is the FCF payout ratio for AbbVie Inc. (ABBV)?
- The FCF payout ratio for ABBV stock is 57.51%.
- Is AbbVie Inc.'s FCF payout ratio high or low?
- AbbVie Inc.'s FCF payout ratio of 57.51% is 13% above its 5-year average of 50.75%, around the middle of its 5-year range (41.42%–65.43%).
- What is the TTM average FCF payout ratio for AbbVie Inc. (ABBV)?
- The TTM average FCF payout ratio for ABBV stock is 63.63%.
- What is the 3Y average FCF payout ratio for AbbVie Inc. (ABBV)?
- The 3Y average FCF payout ratio for ABBV stock is 54.11%.
- What is the 5Y average FCF payout ratio for AbbVie Inc. (ABBV)?
- The 5Y average FCF payout ratio for ABBV stock is 50.75%.
- What is the 10Y average FCF payout ratio for AbbVie Inc. (ABBV)?
- The 10Y average FCF payout ratio for ABBV stock is 49.57%.
- What is the 15Y average FCF payout ratio for AbbVie Inc. (ABBV)?
- The 15Y average FCF payout ratio for ABBV stock is 52.31%.
- What is the 20Y average FCF payout ratio for AbbVie Inc. (ABBV)?
- The 20Y average FCF payout ratio for ABBV stock is 52.31%.
AbbVie Inc. FCF Payout Ratio History
| DATE | FCF PAYOUT RATIO |
|---|---|
| 2025-12-31 | 65.43% |
| 2024-12-31 | 61.83% |
| 2023-12-31 | 47.77% |
| 2022-12-31 | 41.42% |
| 2021-12-31 | 42.11% |
| 2020-12-31 | 45.96% |
| 2019-12-31 | 49.84% |
| 2018-12-31 | 43.63% |
| 2017-12-31 | 43.55% |
| 2016-12-31 | 56.64% |
| 2015-12-31 | 47.04% |
| 2014-12-31 | 90.60% |
| 2013-12-31 | 44.23% |
About AbbVie Inc.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert A. Michael